News

Cupron Performance Additives (“Cupron”) announces new distribution relationship with Palmer Holland

Cupron Performance Additives (Cupron) announced today the launch of an exclusive distribution agreement with Palmer Holland, leading North American distributor of specialty additives for the engineered materials marketplace. Palmer Holland will distribute Cupron’s copper-based antimicrobial and anti-odor technologies into plastics, films, foams, and polymeric systems throughout North America. The Cupron line effectively complements Palmer Holland’s already best-in-class portfolio of specialty additives for plastics.

The Cupron/Palmer Holland partnership offers customers immediate value backed by cutting-edge science and renowned service. Palmer Holland’s deep knowledge of plastic, film, and foam applications will combine synergistically with Cupron’s most time-tested, well-proven antimicrobial and anti-odor technologies. Cupron products are available now for purchase and sampling from Palmer Holland.

Commenting on the partnership, Chris Andrews, Cupron’s Chief Executive Officer, said,

“We were drawn to Palmer Holland’s reputation for its longstanding differentiated market service. Extensive due diligence only validated our assumptions. Where it matters most, our companies overlap in culture and market objectives. Our thanks to Palmer Holland’s talented sales professionals for their vision and enthusiasm during scale-up discussions. We send gratitude and congratulations to Palmer Holland leaders Vince Misiti, Tony Denton, and Jim Norris for their stewardship of a truly great organization.”

Jim Norris, Market Manager for Engineered Materials at Palmer Holland, commented,

“Palmer Holland’s Engineered Materials Business continues to set itself apart with a distribution model designed to deliver unmatched value to suppliers and customers alike. Our new partnership with Cupron is a perfect fit with our strategy of championing specialty additives and modifiers that redefine performance standards. Cupron brings to the plastic-adjacent market a one-of-a-kind technology that combines proven antimicrobial, biocidal, and antifungal protection with a strong sustainability profile—addressing critical needs in product safety, durability, and environmental responsibility.

Through this collaboration, Palmer Holland will connect Cupron’s innovation with leading compounders and masterbatch producers, enabling the creation of next-generation materials that perform better, last longer, and contribute to a healthier planet.”

 

Read more here.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin